Suppr超能文献

基于抗体的肠球菌导管相关尿路感染治疗方法

Antibody-Based Therapy for Enterococcal Catheter-Associated Urinary Tract Infections.

作者信息

Flores-Mireles Ana L, Walker Jennifer N, Potretzke Aaron, Schreiber Henry L, Pinkner Jerome S, Bauman Tyler M, Park Alyssa M, Desai Alana, Hultgren Scott J, Caparon Michael G

机构信息

Department of Molecular Microbiology and Center for Women's Infectious Disease Research, Washington University School of Medicine, Saint Louis, Missouri, USA.

Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA.

出版信息

mBio. 2016 Oct 25;7(5):e01653-16. doi: 10.1128/mBio.01653-16.

Abstract

UNLABELLED

Gram-positive bacteria in the genus Enterococcus are a frequent cause of catheter-associated urinary tract infection (CAUTI), a disease whose treatment is increasingly challenged by multiantibiotic-resistant strains. We have recently shown that E. faecalis uses the Ebp pilus, a heteropolymeric surface fiber, to bind the host protein fibrinogen as a critical step in CAUTI pathogenesis. Fibrinogen is deposited on catheters due to catheter-induced inflammation and is recognized by the N-terminal domain of EbpA (EbpA), the Ebp pilus's adhesin. In a murine model, vaccination with EbpA confers significant protection against CAUTI. Here, we explored the mechanism of protection using passive transfer of immune sera to show that antisera blocking EbpA-fibrinogen interactions not only is prophylactic but also can act therapeutically to reduce bacterial titers of an existing infection. Analysis of 55 clinical CAUTI, bloodstream, and gastrointestinal isolates, including E. faecalis, E. faecium, and vancomycin-resistant enterococci (VRE), revealed a diversity of levels of EbpA expression and fibrinogen-binding efficiency in vitro Strikingly, analysis of 10 strains representative of fibrinogen-binding diversity demonstrated that, irrespective of EbpA levels, EbpA antibodies were universally protective. The results indicate that, despite diversity in levels of fibrinogen binding, strategies that target the disruption of EbpA-fibrinogen interactions have considerable promise for treatment of CAUTI.

IMPORTANCE

Urinary catheterization is a routine medical procedure, and it has been estimated that 30 million Foley catheters are used annually in the United States. Importantly, placement of a urinary catheter renders the patient susceptible to developing a catheter-associated urinary tract infection, accounting for 1 million cases per year. Additionally, these infections can lead to serious complications, including bloodstream infection and death. Enterococcus strains are a common cause of these infections, and management of enterococcal infections has been more difficult in recent years due to the development of antibiotic resistance and the ability of strains to disseminate, resulting in a major threat in hospital settings. In this study, we developed an antibiotic-sparing treatment that is effective against diverse enterococcal isolates, including vancomycin-resistant enterococci, during catheter-associated urinary tract infections.

摘要

未标记

肠球菌属中的革兰氏阳性菌是导管相关尿路感染(CAUTI)的常见病因,这种疾病的治疗正日益受到多重耐药菌株的挑战。我们最近发现,粪肠球菌利用Ebp菌毛(一种异聚体表面纤维)结合宿主蛋白纤维蛋白原,这是CAUTI发病机制中的关键一步。由于导管引发的炎症,纤维蛋白原沉积在导管上,并被Ebp菌毛的黏附素EbpA的N端结构域识别。在小鼠模型中,用EbpA进行疫苗接种可显著预防CAUTI。在此,我们通过被动转移免疫血清来探索保护机制,结果表明,阻断EbpA - 纤维蛋白原相互作用的抗血清不仅具有预防作用,还可在治疗上降低现有感染的细菌滴度。对55株临床CAUTI、血流感染和胃肠道分离株(包括粪肠球菌、屎肠球菌和耐万古霉素肠球菌(VRE))的分析显示,体外EbpA表达水平和纤维蛋白原结合效率存在差异。引人注目的是,对10株代表纤维蛋白原结合多样性的菌株进行分析表明,无论EbpA水平如何,EbpA抗体都具有普遍的保护作用。结果表明,尽管纤维蛋白原结合水平存在差异,但针对破坏EbpA - 纤维蛋白原相互作用的策略在治疗CAUTI方面具有很大的前景。

重要性

导尿是一种常规医疗程序,据估计,美国每年使用3000万根Foley导尿管。重要的是,放置导尿管会使患者易患导管相关尿路感染,每年导致100万例病例。此外,这些感染可导致严重并发症,包括血流感染和死亡。肠球菌菌株是这些感染的常见病因,近年来,由于抗生素耐药性的发展和菌株的传播能力,肠球菌感染的管理变得更加困难,这在医院环境中构成了重大威胁。在本研究中,我们开发了一种抗生素节约型治疗方法,该方法在导管相关尿路感染期间对包括耐万古霉素肠球菌在内的多种肠球菌分离株有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验